The company has not filed an annual or quarterly report since its FY2018 10-K, filed Mar 5, 2019. Its latest SEC filing is a S-8 POS from Nov 13, 2023.
10-K for FY2018, filed Mar 5, 2019
The sections below describe the company as of the FY2018 annual report.
Designs, manufactures and distributes tissue-based, metal and synthetic surgical implants for hospitals, surgeons and medical device companies.
10-K for FY2018, filed Mar 5, 2019RTI Surgical is a global surgical implant company that designs, develops, manufactures and distributes biologic, metal and synthetic…View ↗
We market and distribute our implants through direct distribution channels and a combination of both exclusive and non-exclusive OEM…View ↗
We also market and distribute our implants through relationships with OEM distributors.View ↗
RTI sells implants and is typically paid within 30 to 60 days of delivery; OEM payment is typically due within 30 days of delivery or the start of the contract term. Some OEM agreements include upfront and annual exclusivity fees, while consigned implants are sold when implanted.
10-K for FY2018, filed Mar 5, 2019The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant…View ↗
The Company typically transfers control at a point in time upon shipment or delivery of the implants for direct sales, or upon implantation…View ↗
For the contracts with upfront and annual exclusivity fees, revenue related to those fees is recognized over the contract term following a…View ↗
$280.9M
10-K for FY2018, filed Mar 5, 2019
$280.9M ↗
Hospitals and other healthcare facilities receive implants through RTI’s direct distribution force, representatives and purchasing companies. OEM distributors and independent distributors handle other product lines, including international sales.
10-K for FY2018, filed Mar 5, 2019RTI Surgical is a global surgical implant company that designs, develops, manufactures and distributes biologic, metal and synthetic…View ↗
Marketing and DistributionView ↗
We also market and distribute our implants through relationships with OEM distributors.View ↗
Internationally we market and distribute our implants through a direct distribution organization and a network of independent distributors.View ↗
Domestic distributions and services accounted for 91% of total revenues in 2018. Most of our implants are distributed directly to…View ↗
Not on paper. It lost $1.3M in FY2018, but brought in more cash than it spent: $5.7M of free cash flow.
10-K for FY2018, filed Mar 5, 2019
10-K for FY2018, filed Mar 5, 2019
−$2.5MView ↗
10-K for FY2018, filed Mar 5, 2019
−$1.3MView ↗
10-K for FY2018, filed Mar 5, 2019
$5.7MView ↗
8-K, filed Mar 8, 2019
RTI Surgical® Completes Acquisition of Paradigm SpineView ↗
Held flat. Revenue was $280.9M in FY2018, about the same as the $262.8M of FY2014.
Cardiothoracic hardware
The older report described cardiothoracic cable and plating systems distributed directly and through independent distributors; the latest says RTI sold substantially all related assets and now supplies A&E as an OEM.
10-K for FY2015, filed Mar 7, 2016 10-K for FY2018, filed Mar 5, 2019On August 3, 2017, we completed the sale of substantially all of the assets related to our CT Business to A&E. We now serve as an OEM to…View ↗
Minimally invasive spine products
The older report described spine allografts, synthetic implants, rods, screws and plates; the latest adds Zyga’s minimally invasive lumbar-spine devices, including its sacroiliac joint fusion system.
10-K for FY2015, filed Mar 7, 2016 10-K for FY2018, filed Mar 5, 2019In line with our strategy, on January 4, 2018, we acquired Zyga Technology, Inc. (“Zyga”), a leading spine-focused medical device company…View ↗
Competes with Musculoskeletal Transplant Foundation, AlloSource, Community Tissue Services, LifeLink Tissue Bank, JRF Ortho, LifeCell, LifeNet Health, Integra, Wright Medical, Baxter, Cook Surgical, Medtronic, Stryker, Zimmer Biomet, Depuy Synthes, Globus Medical Group, K2M Group Holdings, NuVasive, Alphatec Holdings, and Orthofix International
10-K for FY2018, filed Mar 5, 2019Our principal competitors in the conventional allograft market include the Musculoskeletal Transplant Foundation (“MTF”), AlloSource Inc.…View ↗
Loading...
